# K072638

# OCT 19 2007 510(k) Summary - Roche/Hitachi Urinary/CSF Protein

# Introduction and purpose of submission

Roche Diagnostics Corporation hereby submits this Special 510(k): Device Modification to provide notification of modifications to our Urine/CSF Protein test system. The reagent was originally cleared as an endpoint, turbidimetric assay for use as Roche/Hitachi Urinary/CSF Protein via K913615. Subsequent to this filing, a rate (kinetic) application was developed, in addition to the original endpoint assay, and applied to the Hitachi family of analyzers. This additional rate application did not involve any changes to the reagent formulation, and is the sole purpose of this Special 510(k).

Continued on next page

# 510(k) Summary - Roche/Hitachi Urinary/CSF Protein, Continued

Submitter name, address, contact

Roche Diagnostics 9115 Hague Rd Indianapolis IN 46250 (317) 521-7637

Contact person: Kerwin Kaufman

Date prepared: September 17, 2007

# Device Name

Proprietary name: Roche/Hitachi Urinary/CSF Protein Common name: Total Protein Classification name: Total Protein test system

# Classification

The FDA has classified Total protein test system in Class II.   

<table><tr><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>ClassificationNumber</td><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>RegulationCitation</td></tr><tr><td rowspan=1 colspan=1>75 ClinicalChemistry</td><td rowspan=1 colspan=1>JGQ</td><td rowspan=1 colspan=1>Total Protein test system</td><td rowspan=1 colspan=1>21 CFR 862.1635</td></tr></table>

# Establishment registration

The establishment registration number for Roche Diagnostics GmbH Penzberg is 9610529.

The establishment registration number for Roche Diagnostics Corporation Indianapolis is 1823260.

# Device Description

The Roche/Hitachi Urinary/CSF Protein reagent is an in vitro test for the quantitative determination protein in urineand cerebrospinal fluid o Roche automated clinical chemistry analyzers.

The modified device includes both the original endpoint assay and the additional rate assay. The new rate assay was developed to provide absorbance limits that will flag high protein samples with high absorbance, thus eliminating the need for prescreening samples for high protein levels. The endpoint assay stil requires sample prescreening or inspection of the Reaction Monitor display after completion of the reaction to ensure that high samples are detected and appropriately diluted for rerun. The attached labeling provides a more complete description of this potential high sample / prozone effect.

# Intended use and Summary

# Intended Use

The Roche/Hitachi Urinary/CSF Protein reagent is an in vitro test for the quantitative determination of protein in urine and cerebrospinal fluid on Roche automated clinical chemistry analyzers.

# Summary

Protein measurements in urine are used in the diagnosis and treatment of disease conditions such as renal or heart diseases, or thyroid disorders, which are characterized by proteinuria or albuminuria.

CSF protein measurements are used in diagnosis and treatment of disease conditions such as meningitis, brain tumors and infections of the central nervous systems.

# Predicate Device

We claim substantial equivalence to the Hitachi Urinary/CSF Protein test system cleared as K913615.

Substantial equivalency Similarities

The table below indicates the similarities and differences between the modified Urinary/CSF Protein reagent and the predicate device.

# 510(k) Summary - Roche/Hitachi Urinary/CSF Protein, Continued

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate device:Roche/Hitachi Urinary/CSF ProteinK913615</td><td rowspan=1 colspan=1>Modified device:Roche/Hitachi Urinary/CSFProtein, Additional RATEApplication</td></tr><tr><td rowspan=1 colspan=3>General</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the quantitative determination ofprotein in urine (U) and cerebrospinalfluid (CSF).</td><td rowspan=1 colspan=1>In vitro test for the quantitativedetermination of protein in urineand cerebrospinal fluid on Rocheautomated clinical chemistryanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Urine and CSF</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Application</td><td rowspan=1 colspan=1>Endpoint assay</td><td rowspan=1 colspan=1>Endpoint and Rate application</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatforms</td><td rowspan=1 colspan=1>Roche/Hitachi analyzers</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Test Principle                                                                                    </td></tr><tr><td rowspan=1 colspan=1>Referencemethod</td><td rowspan=1 colspan=1>Turbidimetric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Reagent information</td></tr><tr><td rowspan=1 colspan=1>Reagentcomposition</td><td rowspan=1 colspan=1>R1: Sodium hydroxide 530 mmol/L,EDTA sodium, 74 mmol/LR2: Benzethonium chloride 32 mmol/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability - shelflife and on-board</td><td rowspan=1 colspan=1>20-25 °C until expiration dateR1: 3 weeks on board at 2-12 CR2: 3 weeks on board at 2-12 °C</td><td rowspan=1 colspan=1>15-25 °C until expiration dateR1: 21 days on board andrefrigerated on the analyzerR2: 21 days on board andrefrigerated on the analyzer</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Preciset U/CSF Protein5 levels: 10, 20, 40, 80, 200 mg/dL0.9 % NaCl used for a 0 mg/dL level</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Quality control</td><td rowspan=1 colspan=1>Commercially available urine and CSFprotein controls</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>This method has been standardizedagainst the National Bureau ofStandards Reference Material SRM927a using the biuret method for thequantitation of protein.</td><td rowspan=1 colspan=1>Same</td></tr></table>

Substantial equivalency - Similarities

<table><tr><td rowspan=1 colspan=1>EY</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=6>Predicate device:Roche/Hitachi Urinary/CSF ProteinK913615</td><td rowspan=1 colspan=20>Modified device:Roche/Hitachi Urinary/CSF Protein,Additional RATE Application</td></tr><tr><td rowspan=1 colspan=27>Performance characteristics                                            0                       ,&quot;&quot;yo   :</td></tr><tr><td></td><td rowspan=5 colspan=6>Urine: (data from K913615 labeling,page 33)Urine                  Within-run (n = 120)Sample            Mean     SD      CVmg/dL    mg/al      90</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=3>Urine</td><td rowspan=1 colspan=2>Within-run (n = 21)</td><td rowspan=1 colspan=1>= 21)</td><td rowspan=1 colspan=3>Between-run (n = 10)</td><td rowspan=1 colspan=11>1 = 10)</td></tr><tr><td></td><td rowspan=3 colspan=1>Sample</td><td rowspan=1 colspan=2></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=3 colspan=1>Meanmg/dL</td><td rowspan=3 colspan=1>SDmg/al</td><td rowspan=3 colspan=1>CV90</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=2 colspan=2></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=2>Sample</td><td rowspan=1 colspan=1>Meanmg/dL</td><td rowspan=1 colspan=1>SDmg/dL</td><td rowspan=1 colspan=1>$Cv$</td><td rowspan=1 colspan=1>Meanmgidl</td><td rowspan=1 colspan=2>SDmgridL</td><td rowspan=1 colspan=11>CV.0</td></tr><tr><td></td><td rowspan=6 colspan=1></td><td rowspan=1 colspan=1>Control 1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>6.4</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=2>0.46</td><td rowspan=1 colspan=11>3.8</td><td rowspan=1 colspan=2>Control 2</td><td rowspan=1 colspan=1>22.4</td><td rowspan=1 colspan=2>0.30</td><td rowspan=1 colspan=2>1.4</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>21.7</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>34.5</td><td rowspan=1 colspan=2>0.60</td><td rowspan=1 colspan=11>1.7</td><td rowspan=1 colspan=2>Control 3</td><td rowspan=1 colspan=1>182.4</td><td rowspan=1 colspan=2>0.90</td><td rowspan=1 colspan=2>0.5</td><td rowspan=1 colspan=1>67.3</td><td rowspan=1 colspan=1>0.66</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=2>Total (n = 120)</td><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Meanmg/dL</td><td rowspan=1 colspan=1>SDmgidL</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.65</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>22.4</td><td rowspan=1 colspan=1>0.55</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>182.4</td><td rowspan=1 colspan=1>1.60</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-run</td><td rowspan=1 colspan=1></td><td></td><td></td><td rowspan=1 colspan=2>CSF</td><td rowspan=1 colspan=3>Within-run ({n = 20)</td><td rowspan=1 colspan=1>Betwe</td><td></td><td></td><td></td><td rowspan=1 colspan=1>CSF</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=4 colspan=1>Sample</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=2 colspan=11>en-run I</td><td rowspan=2 colspan=11>n = 10)</td></tr><tr><td></td><td></td><td></td><td rowspan=2 colspan=1>Meanmg/dL</td><td rowspan=2 colspan=1>SDmg/dl</td><td rowspan=2 colspan=1>CV9$</td><td rowspan=2 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td rowspan=2 colspan=3>Sample</td><td rowspan=2 colspan=1>Meanmg/dL</td><td rowspan=2 colspan=1>SDmg&#x27;dL</td><td rowspan=2 colspan=1>CV0</td><td rowspan=2 colspan=1>Meanmg&#x27;dL</td><td></td><td rowspan=2 colspan=11>SDmg/dt.</td><td rowspan=2 colspan=1>CV%</td><td></td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>3.7</td><td></td><td></td><td rowspan=1 colspan=1>Control1(n=120)</td><td></td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>1.3</td><td></td><td></td><td></td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>23.1</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>29.3</td><td></td><td rowspan=1 colspan=11>0.30</td><td rowspan=1 colspan=1>1.0</td><td></td></tr><tr><td></td><td></td><td></td><td rowspan=1 colspan=1>81.0</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.7</td><td></td><td></td><td></td><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>53.6</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>90.2</td><td></td><td rowspan=1 colspan=11>0.56</td><td rowspan=1 colspan=1>0.6</td><td></td></tr><tr><td></td><td rowspan=6 colspan=26>CSF                         TotalSample            Mean     SD      CVmgidL    mg/dL     %Control1(n=120)     11.4     0.59      5.1Control 2(n=119)    23.8     0.49     2.0Control 3(n=119    81.0     0.74     0.9</td><td rowspan=1 colspan=1></td></tr><tr><td></td><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=1>CSF</td></tr><tr><td></td><td rowspan=1 colspan=1>MeanmgidL</td><td rowspan=1 colspan=1>SDmg/dL</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Sample</td></tr><tr><td></td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>Control1(n=120)</td></tr><tr><td></td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>Control 2(n=119)</td></tr><tr><td></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>81.0</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>Control 3(n=119</td></tr></table>

# 510(k) Summary  Roche/Hitachi Urinary/CSF Protein, Continued

Substantial equivalency - Similarities (continued)

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate device:Roche/Hitachi Urinary/CSF ProteinK913615</td><td rowspan=1 colspan=1>Modified device:Roche/Hitachi Urinary/CSF Protein,Additional RATE Application</td></tr><tr><td rowspan=1 colspan=1>Measuringrange</td><td rowspan=1 colspan=1>Endpoint Assay:2-200 mg/dLIf results exceed the upper limit of themeasuring range, dilute the specimenwith isotonic saline and repeat theassay.</td><td rowspan=1 colspan=1>Endpoint Assay:2-200 mg/dLRate Assay:6-200 mg/dLDetermine samples with U/CSFprotein concentrations &gt; 200 mg/dl(2000 mg/L) via the rerun function.On instruments without rerunfunction, manually dilute sampleswith 0.9% NaCl. Multiply theresult by the appropriate dilutionfactor.</td></tr><tr><td rowspan=1 colspan=1>Lowerdetection limit</td><td rowspan=1 colspan=1>2 mg/dL</td><td rowspan=1 colspan=1>Endpoint Assay:2 mg/dLRate Assay6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Expectedvalues(literaturereference</td><td rowspan=1 colspan=1>Urine Random: &lt; 12 mg/dLUrine 24h: &lt; 150 mg/dayCSF: 15-45 mg/dL</td><td rowspan=1 colspan=1>Urine 24h: &lt; 150 mg/dayCSF: 15-45 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Endogenousinterferences**</td><td rowspan=1 colspan=1>Hemolysis or RBC contaminationinterferes with the assayReference to Young et aland Friedman et al</td><td rowspan=1 colspan=1>Icterus: No significant interferenceup to an I index of 36 (approximateconjugated concentration: 36mg/dL or 615 μmol/L).Hemolysis: Hemoglobin interferes.</td></tr></table>

\*\* Dat nteerences appl to both the edpoint and theadiinal rateapplicin

# 510(k) Summary  Roche/Hitachi Urinary/CSF Protein, Continued

Substantial equivalency - Similarities (continued)

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate device:Roche/Hitachi Urinary/CSF ProteinK913615</td><td rowspan=1 colspan=1>Modified device:Roche/Hitachi Urinary/CSF Protein,Additional RATE Application</td></tr><tr><td rowspan=1 colspan=1>Exogenousinterferences**</td><td rowspan=1 colspan=1>There is no significant interferencefrom the following substances:Ascorbic Acid, Creatinine, Glucose,Phosphorus, Urea, Magnesium,Sodium Citrate, Caffeine, CefazolinSodium, Chlorpromazine, Calcium L-Dopa, Gentamicin Sulfate, SodiumOxalate and Uric Acid</td><td rowspan=1 colspan=1>No significant interference from:Ascorbic Acid, Creatinine, Glucose,Phosphorus, Urea, Magnesium,Sodium Citrate, Caffeine, CefazolinSodium, Chlorpromazine, CalciumL-Dopa, Gentamicin Sulfate,Sodium Oxalate and Uric AcidTherapeutic concentrations of Ca-dobesilate, levodopa andphenazopyridine interfere with theassay.The administration of gelatin-basedplasma replacements canlead to increased urine proteinvalues.In very rare cases gammopathy, inparticular type IgM (Waldenström&#x27;smacroglobulinemia), may causeunreliable results.</td></tr></table>

\*\* Data on interferences applies to both the endpoint and the additional rate application

# 510(k) Summary - Roche/Hitachi Urinary/CSF Protein, Continued

Substantial equivalency - Similarities (continued)   

<table><tr><td>Feature</td><td>Predicate device: Roche/Hitachi Urinary/CSF Protein K913615</td><td>Modified device: Roche/Hitachi Urinary/CSF Protein, Additional RATE Application</td></tr><tr><td>Method comparison</td><td>A comparison of this method on the Hitachi 717 analyzer using the DuPont ACA method as the reference resulted in the following linear regression statistics: Urine samples: y= 1.051x +2.78 r= 0.996 n=34 CSF samples: y = 0.992x - 0.957 r= 0.982 n=59</td><td>A comparison of the U/CSF Protein determination with Roche Diagnostics U/CSF Protein reagent using the rate application (y) with the same reagent using the endpoint application (x) gave the following correlations (mg/dL): Urine samples: Passing/Bablok y = 0.988x - 0.434 r = 1.000 Number of samples measured: 60 The sample concentrations were</td></tr><tr><td></td><td></td><td>between 1.7 and 3286.5 mg/dL. Statistics include all results (diluted and undiluted). CSF samples:</td></tr><tr><td></td><td></td><td>Passing/Bablok y = 0.984x + 0.480 r=1.000</td></tr><tr><td></td><td></td><td>Number of samples measured: 50 The sample concentrations were between 5.8 and 110.2 mg/dL.</td></tr></table>

# 510(k) Summary - Roche/Hitachi Urinary/CSF Protein, Continued

# Proposed Labeling

Proposed labeling sufficient to describe the device, its intended use, and the directions for use are included. We believe the proposed version of the device labeling presented contains al of the technical information required per 21 CFR 809.10.

# Validation and Design Control

Development activities were conducted under appropriate design control procedures and the overall product specifications were met. The Declaration of Conformity with Design Controls and Results of Risk Analysis are provided.

#

The modification of the Roche/Hitachi Urinary/CSF Protein reagent described above does not affect the intended use or indications for use of the device as described in the labeling, nor does it alter the fundamental scientific technology of the device. Therefore, we trust the information provided in this Special 510(k) will support a decision of substantial equivalence of the Roche/Hitachi Urinary/CSF Protein with the Rate application to its predicate.

If you have any questions or require further information, please do not hesitate to contact this office.

Kerwin Kaufman, MBA, MT(ASCP)

Regulatory Affairs Principal Roche Diagnostics Phone: (317) 521-7637 FAX: (317) 521-2324 email: Kerwin.Kaufman@roche.com

Roche Diagnostics Corp. c/o Mr. Kerwin L. Kaufman Regulatory Affairs Principal 9115 Hague Road Indianapolis, IN 46250-0416

Re: k072638 Trade/Device Name: Roche/Hitachi Urinary/CSF Protein Regulation Number: 21 CFR 862.1635 Regulation Name: Total Protein test system. Regulatory Class: Class II Product Code: JGQ Dated: September 17, 2007 Received: September 18, 2007

Dear Mr. Kaufman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class I (PMA), it may be subject to such additional controls. Existing major regulations afecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S., D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known):

Device Name: Roche/Hitachi Urinary/CSF Protein

Indications For Use:

In vitro test for the quantitative determination of protein in urine and cerebrospinal fluid on Roche automated clinical chemistry analyzers.

Measurements obtained by this device are used in the diagnosis and treatment of a variety of diseases involving the liver, kidney or bone marow as well as metabolic or nutritional disorders.

Protein measurements in urine are used in the diagnosis and treatment of disease conditions such as renal or heart diseases, or thyroid disorders, which are characterized by proteinuria or albuminuria.

CSF protein measurements are used in diagnosis and treatment of conditions such as meningitis, brain tumors and infections of the central nervous systems.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Cawf Bena

Page 1 of

ice of In Vitro Diagnostic Device uation and Safety